Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410Phase 3Recruiting
- Lead sponsor
- Regeneron Pharmaceuticals (Industry)
- Enrollment
- 369 (estimated)
- Start date
- 2 Jan 2025
- Primary completion
- 3 May 2030 (estimated)
- Study completion
- 3 May 2030
- Last update posted
- 16 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Cemiplimab Drug
- Standard of care Procedure
Conditions and primary outcome
- Cutaneous Squamous Cell Carcinoma (CSCC)
Primary outcome
Event-Free Survival (EFS) as assessed by the investigator (Up to 1 year); EFS as assessed by the investigator (Up to 3 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06585410.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06585410 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.